CA3234321A1 - Lipid nanoparticles used to transport nucleic acids into lymphatic endothelium cells - Google Patents

Lipid nanoparticles used to transport nucleic acids into lymphatic endothelium cells Download PDF

Info

Publication number
CA3234321A1
CA3234321A1 CA3234321A CA3234321A CA3234321A1 CA 3234321 A1 CA3234321 A1 CA 3234321A1 CA 3234321 A CA3234321 A CA 3234321A CA 3234321 A CA3234321 A CA 3234321A CA 3234321 A1 CA3234321 A1 CA 3234321A1
Authority
CA
Canada
Prior art keywords
group
carbon atoms
lipid
formula
independently
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3234321A
Other languages
English (en)
French (fr)
Inventor
Kota TANGE
Hiroki Yoshioka
Yuta Nakai
Hidetaka Akita
Yu SAKURAI
Hiroki Tanaka
Keito YOSHIKAWA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chiba University NUC
NOF Corp
Original Assignee
Chiba University NUC
NOF Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiba University NUC, NOF Corp filed Critical Chiba University NUC
Publication of CA3234321A1 publication Critical patent/CA3234321A1/en
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/713Double-stranded nucleic acids or oligonucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5107Excipients; Inactive ingredients
    • A61K9/5123Organic compounds, e.g. fats, sugars
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/14Type of nucleic acid interfering nucleic acids [NA]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3234321A 2021-09-30 2022-09-26 Lipid nanoparticles used to transport nucleic acids into lymphatic endothelium cells Pending CA3234321A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2021161239 2021-09-30
JP2021-161239 2021-09-30
PCT/JP2022/035637 WO2023054242A1 (ja) 2021-09-30 2022-09-26 核酸をリンパ管内皮細胞に送達するために用いられる脂質ナノ粒子

Publications (1)

Publication Number Publication Date
CA3234321A1 true CA3234321A1 (en) 2023-04-06

Family

ID=85782634

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3234321A Pending CA3234321A1 (en) 2021-09-30 2022-09-26 Lipid nanoparticles used to transport nucleic acids into lymphatic endothelium cells

Country Status (6)

Country Link
US (1) US20250197852A1 (https=)
EP (1) EP4410276A4 (https=)
JP (1) JPWO2023054242A1 (https=)
CN (1) CN118251212A (https=)
CA (1) CA3234321A1 (https=)
WO (1) WO2023054242A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4501361A4 (en) * 2022-03-28 2026-01-28 Nof Corp Lipid nanoparticles for delivering nucleic acid to peripheral blood mononuclear cells, and a method for delivering nucleic acid to peripheral blood mononuclear cells using them

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019188867A1 (ja) 2018-03-27 2019-10-03 日油株式会社 細胞内動態を改善した新規カチオン性脂質
EP3906039A4 (en) * 2019-01-04 2023-01-18 Oncorus, Inc. ENCAPSULATED POLYNUCLEOTIDES AND METHODS OF USE
WO2020206231A1 (en) * 2019-04-05 2020-10-08 Precision Biosciences, Inc. Methods of preparing populations of genetically-modified immune cells
JP7700101B2 (ja) * 2019-09-06 2025-06-30 ジェネレーション バイオ カンパニー 閉端dnaおよび切断可能脂質を含む脂質ナノ粒子組成物ならびにそれらの使用方法
WO2021060440A1 (ja) * 2019-09-26 2021-04-01 日油株式会社 脂質ナノ粒子の凍結乾燥組成物
IL296763B2 (en) * 2020-03-27 2026-04-01 Generation Bio Co New lipids and their nanoparticle compositions

Also Published As

Publication number Publication date
US20250197852A1 (en) 2025-06-19
JPWO2023054242A1 (https=) 2023-04-06
WO2023054242A1 (ja) 2023-04-06
EP4410276A1 (en) 2024-08-07
EP4410276A4 (en) 2025-10-22
CN118251212A (zh) 2024-06-25

Similar Documents

Publication Publication Date Title
KR102674501B1 (ko) 세포 내 동태를 개선한 신규 양이온성 지질
JP6640750B2 (ja) カチオン性脂質
EP4035686A1 (en) Lipid nanoparticle lyophilized composition
AU710170B2 (en) Cationic virosomes as transfer system for genetic material
JP2002521423A (ja) 遺伝子又は薬物運搬体としての脂質エマルジョン及び固形脂質微粒子
EP4501360A1 (en) Lipid nanoparticles for delivering nucleic acid to splenic tissue, and method for delivering nucleic acid to splenic tissue using same
Yang et al. Dual-targeted lipid nanoparticles system for synergistic anti-inflammation and cartilage repair in the treatment of temporomandibular joint osteoarthritis
US20250057977A1 (en) Lipid nanoparticles having cell directivity
EP4410276A1 (en) Lipid nanoparticles used to transport nucleic acids into lymphatic endothelium cells
EP4410275A1 (en) Lipid nanoparticle used for delivering nucleic acid to brain tissue
WO1999021533A2 (en) Delivery vehicles for bioactive agents and uses thereof
US20260115316A1 (en) Lipid nanoparticles for delivering nucleic acid to splenic tissue, and method for delivering nucleic acid to splenic tissue using same
EP4555999A1 (en) Lipid nanoparticle and method for producing same, nucleic acid-encapsulated lipid nanoparticle and method for producing same, and method for inducing acquired immunity in living body by using nucleic acid-encapsulated lipid nanoparticle
EP4691476A1 (en) Method for producing nucleic acid-encapsulated lipid nanoparticles
EP4501361A1 (en) Lipid nanoparticles for delivering nucleic acid to peripheral blood mononuclear cells, and method for delivering nucleic acid to peripheral blood mononuclear cells using same
CA3287902A1 (en) Method for producing nucleic acid-encapsulated lipid nanoparticles
Düzgünes et al. Intracellular delivery of therapeutic oligonucleotides in pH-sensitive and cationic liposomes
WO2025063214A1 (ja) 核酸を内封したリガンド修飾脂質ナノ粒子の製造方法
Zhao Non-Viral Intracellular mRNA Delivery to Hard-To-Transfect Cells Using Synthetic Lipidoid Nanoparticles
KR101671864B1 (ko) 요오드화 오일을 함유하는 양이온성 에멀젼 및 바이러스 벡터의 유전자 전달 증진을 위한 이의 용도

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240726

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240726

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250730

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250730